TWI867299B - 用於治療或預防伴隨抗癌劑之投予之傷害的醫藥組合物 - Google Patents

用於治療或預防伴隨抗癌劑之投予之傷害的醫藥組合物 Download PDF

Info

Publication number
TWI867299B
TWI867299B TW111118516A TW111118516A TWI867299B TW I867299 B TWI867299 B TW I867299B TW 111118516 A TW111118516 A TW 111118516A TW 111118516 A TW111118516 A TW 111118516A TW I867299 B TWI867299 B TW I867299B
Authority
TW
Taiwan
Prior art keywords
cancer
sod
superoxide dismutase
administration
tumor
Prior art date
Application number
TW111118516A
Other languages
English (en)
Chinese (zh)
Other versions
TW202313100A (zh
Inventor
喬志偉
本田愛美
秋元匠太
佐佐木友樹
梶紀子
福田耕一郎
水島徹
田中健一郎
Original Assignee
日商日本股份有限公司Ltt生物醫藥
學校法人武藏野大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商日本股份有限公司Ltt生物醫藥, 學校法人武藏野大學 filed Critical 日商日本股份有限公司Ltt生物醫藥
Publication of TW202313100A publication Critical patent/TW202313100A/zh
Application granted granted Critical
Publication of TWI867299B publication Critical patent/TWI867299B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111118516A 2021-05-18 2022-05-18 用於治療或預防伴隨抗癌劑之投予之傷害的醫藥組合物 TWI867299B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021-083610 2021-05-18
JP2021083610 2021-05-18

Publications (2)

Publication Number Publication Date
TW202313100A TW202313100A (zh) 2023-04-01
TWI867299B true TWI867299B (zh) 2024-12-21

Family

ID=84141593

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111118516A TWI867299B (zh) 2021-05-18 2022-05-18 用於治療或預防伴隨抗癌劑之投予之傷害的醫藥組合物

Country Status (11)

Country Link
US (1) US20240261375A1 (cg-RX-API-DMAC7.html)
EP (1) EP4353251A4 (cg-RX-API-DMAC7.html)
JP (1) JP7504367B2 (cg-RX-API-DMAC7.html)
KR (1) KR102843447B1 (cg-RX-API-DMAC7.html)
CN (1) CN117279657A (cg-RX-API-DMAC7.html)
AU (1) AU2022278242B2 (cg-RX-API-DMAC7.html)
CA (1) CA3220333A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023017275A2 (cg-RX-API-DMAC7.html)
MX (1) MX428431B (cg-RX-API-DMAC7.html)
TW (1) TWI867299B (cg-RX-API-DMAC7.html)
WO (1) WO2022244757A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024411340A1 (en) 2023-12-26 2026-06-18 Ltt Bio-Pharma Co., Ltd. Prophylactic and therapeutic agent for diseases caused by type i allergic reaction induced by anticancer agent
WO2025178511A1 (ru) * 2024-02-21 2025-08-28 Евгений Владимирович ГРИГОРЬЕВ Применение супероксиддисмутазы 2 в качестве антиоксиданта в сверхмалых дозировках

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040980A1 (ja) * 2004-10-12 2006-04-20 Asahi Glass Company, Limited レシチン化スーパーオキシドディスムターゼ組成物およびその製造方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653670B2 (ja) * 1985-10-28 1994-07-20 日研フ−ド株式会社 化学療法剤の副作用低減化剤
JPH04135485A (ja) * 1990-09-28 1992-05-08 Seikagaku Kogyo Co Ltd 白金錯体及び抗腫瘍剤
JP3232542B2 (ja) 1993-01-08 2001-11-26 宇部興産株式会社 ヒトCu,Zn型スーパーオキシドジスムターゼ誘導体及びその製造法
JPH08208511A (ja) * 1995-01-31 1996-08-13 Samu Kenkyusho:Kk 抗運動ニューロン疾患剤
US6221848B1 (en) * 1998-05-11 2001-04-24 University Of Pittsburgh Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
JP2001002585A (ja) * 1999-06-22 2001-01-09 Ltt Kenkyusho:Kk レシチン化スーパーオキシドジスムターゼ含有抗線維化剤
JP3792487B2 (ja) 1999-06-24 2006-07-05 株式会社Lttバイオファーマ レシチン化スーパーオキシドジスムターゼ含有医薬組成物
EP1292324A2 (en) 2000-05-05 2003-03-19 Novo Nordisk A/S Critical illness neuropathy
JP2002080395A (ja) * 2000-08-31 2002-03-19 Ltt Institute Co Ltd 心筋傷害処置剤
WO2004065410A2 (en) 2003-01-21 2004-08-05 Genervon Biopharmaceuticals Llc Mntf peptides and compositions and methods of use
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
JP2006169128A (ja) 2004-12-13 2006-06-29 Ltt Bio-Pharma Co Ltd 熱傷治療剤
JP4867540B2 (ja) 2006-09-20 2012-02-01 日本精工株式会社 無段変速装置
CA2671668A1 (en) * 2006-12-19 2008-06-26 Ltt Bio-Pharma Co., Ltd. Therapeutic composition for interstitial pheumonia
JP5459827B2 (ja) 2009-03-13 2014-04-02 株式会社Lttバイオファーマ 慢性閉塞性肺疾患改善剤
JP6231386B2 (ja) 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
BR112014016497B1 (pt) 2012-01-05 2021-02-23 Pledpharma Ab complexos de metal misturados, composição farmacêutica compreendendo os mesmos, métodos de produção e uso
JP6545926B2 (ja) * 2012-11-30 2019-07-17 株式会社ナノエッグ 手足症候群治療用組成物
KR20170036753A (ko) 2014-07-31 2017-04-03 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화학요법 유도된 말초 신경병증 (cipn)의 예방 및/또는 치료를 위한 cxcr2 길항제의 용도
EP2985036A3 (en) 2014-08-14 2016-03-09 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. CYP2J2 antagonists in the treatment of pain
JP6851639B2 (ja) 2015-07-16 2021-03-31 ゾミクス バイオファーマ, インコーポレイテッド プラチナ薬剤の毒性の予防方法
JP6650612B2 (ja) 2015-10-06 2020-02-19 パナソニックIpマネジメント株式会社 照明制御装置及び照明システム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040980A1 (ja) * 2004-10-12 2006-04-20 Asahi Glass Company, Limited レシチン化スーパーオキシドディスムターゼ組成物およびその製造方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
期刊 Kim ST, et al. Phosphatidylcholine attenuated docetaxel-induced peripheral neurotoxicity in rats. Drug Chem Toxicol. 41 2017/12/06 476-485
期刊 Kim ST, et al. Phosphatidylcholine attenuated docetaxel-induced peripheral neurotoxicity in rats. Drug Chem Toxicol. 41 2017/12/06 476-485; *
期刊 Kim ST, et al. Protective effects of phosphatidylcholine on oxaliplatin-induced neuropathy in rats. Life Sci. 130 2015/03/25 81-87
期刊 Kim ST, et al. Protective effects of phosphatidylcholine on oxaliplatin-induced neuropathy in rats. Life Sci. 130 2015/03/25 81-87; *
期刊 太田 有紀, 武永 美津子, 都倉 享恵, 濱口 明美, 山口 葉子, 中村 雅也, 岡野 栄之, 五十嵐 理慧 外傷性脊髄損傷後のレシチン修飾SOD投与の有用性 Inflammation and Regeneration 26 2006/08/18 113-120 *

Also Published As

Publication number Publication date
AU2022278242B2 (en) 2024-11-14
MX2023013777A (es) 2023-12-04
CA3220333A1 (en) 2022-11-24
BR112023024140A2 (pt) 2024-02-06
KR102843447B1 (ko) 2025-08-06
EP4353251A1 (en) 2024-04-17
CN117279657A (zh) 2023-12-22
CO2023017275A2 (es) 2023-12-20
JPWO2022244757A1 (cg-RX-API-DMAC7.html) 2022-11-24
KR20240008844A (ko) 2024-01-19
JP7504367B2 (ja) 2024-06-24
AU2022278242A1 (en) 2023-11-30
WO2022244757A1 (ja) 2022-11-24
TW202313100A (zh) 2023-04-01
MX428431B (es) 2025-11-13
EP4353251A4 (en) 2025-05-14
US20240261375A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
Qiao et al. Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan
Hu et al. E Platinum, a newly synthesized platinum compound, induces autophagy via inhibiting phosphorylation of mTOR in gastric carcinoma BGC-823 cells
JP2009504679A (ja) Vegfアンタゴニストを用いて疾患を処置する方法
EP3263107B1 (en) Block copolymer conjugate of physiologically active substance
KR20110025178A (ko) Pm00104 및 다른 항종양제를 이용한 복합 치료법
JP7504367B2 (ja) 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物
CN111744020A (zh) 一种主动靶向响应型多肽药物、其制备方法和应用
ES2935705T3 (es) Un ligando del receptor GABA A
CN114621325A (zh) 一种纤连蛋白靶向多肽及其在促进肿瘤失巢凋亡及化疗增敏中的应用
RU2845522C2 (ru) Фармацевтическая композиция для лечения или профилактики расстройства, связанного с введением противоракового средства
CA2807707A1 (en) Compositions and methods for treating cancer
JP6629753B2 (ja) がん治療剤の組合せ
HK40100859A (en) Pharmaceutical composition for treating or preventing disorder associated with administration of anticancer agent
KR102371980B1 (ko) 췌장암 예방 또는 치료용 조성물
US20160074468A1 (en) Combination anti-her2 cancer therapy using muc1 peptides and chemotherapeutics
CN116234541A (zh) 通过EpoR拮抗剂治疗疾病
BR112023024140B1 (pt) Uso de uma superóxido dismutase lecitinizada para tratar ou prevenir um distúrbio associado com a administração de um agente anticâncer
HK1212920A1 (zh) 使用麦胶蛋白肽治疗癌症的套件和方法
US11980667B2 (en) Short TAT oligomers for drug delivery
WO2024148356A1 (en) Nanoparticle-nhe3 peptide to treat diarrhea
KR20250022385A (ko) 말초신경 퇴행성 질환의 예방 또는 치료용 약학 조성물
CN112294829A (zh) 红景天苷在制备治疗或预防癌症的药物中的应用
HK40008907A (en) Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients
Annunzi N-Myristoylation
WO2014020211A1 (es) Línea celular de cáncer de mama y su uso en la identificación de compuestos candidatos para el tratamiento de dicha enfermedad